Gilead Sciences, Inc. (GILD) Hits New 52-Week Low After Analyst Downgrade, Report finds

Gilead Sciences, Inc. (GILD) Hits New 52-Week Low After Analyst Downgrade, Report finds

Gilead Sciences, Inc. (NASDAQ:GILD) shares hit a new 52-week low during trading on Wednesday after RBC Capital Markets lowered their price target on the stock to $75.00. The company traded as low as $65.83 and last traded at $65.81, with a volume of 3,304,798 shares. The stock had previously closed at $73.13.

GILD has been the subject of a number of other research reports. William Blair reiterated an “outperform” rating on shares of Gilead Sciences in a research note on Saturday, January 28th. Cowen and Company set a $100.00 target price on shares of Gilead Sciences and gave the company a “buy” rating in a research note on Wednesday, January 18th. Evercore ISI set a $90.00 target price on shares of Gilead Sciences and gave the company a “buy” rating in a research note on Saturday, October 15th. Goldman Sachs Group, Inc. (The) reiterated a “hold” rating and issued a $81.00 target price on shares of Gilead Sciences in a research note on Friday, January 13th. Finally, Robert W. Baird reiterated an “outperform” rating and issued a $100.00 target price (down previously from $122.00) on shares of Gilead Sciences in a research note on Tuesday, October 18th. One equities research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, fourteen have given a buy rating and two have issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $90.68.

In other Gilead Sciences news, insider John C. Martin sold 73,337 shares of Gilead Sciences stock in a transaction dated Tuesday, January 3rd. The shares were sold at an average price of $73.59, for a total value of $5,396,869.83. Following the sale, the insider now owns 3,204,433 shares of the company’s stock, valued at $235,814,224.47. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director John W. Madigan sold 105,000 shares of Gilead Sciences stock in a transaction dated Friday, November 18th. The stock was sold at an average price of $74.86, for a total transaction of $7,860,300.00. Following the completion of the sale, the director now directly owns 121,761 shares in the company, valued at approximately $9,115,028.46. The disclosure for this sale can be found here. Corporate insiders own 1.40% of the company’s stock.

Institutional investors have recently bought and sold shares of the company. Tarbox Group Inc. increased its position in Gilead Sciences by 0.4% in the third quarter. Tarbox Group Inc. now owns 6,522 shares of the biopharmaceutical company’s stock valued at $516,000 after buying an additional 27 shares during the last quarter. West Oak Capital LLC increased its position in Gilead Sciences by 0.7% in the third quarter. West Oak Capital LLC now owns 4,449 shares of the biopharmaceutical company’s stock valued at $352,000 after buying an additional 32 shares during the last quarter. Alpha Windward LLC increased its position in Gilead Sciences by 1.0% in the third quarter. Alpha Windward LLC now owns 3,410 shares of the biopharmaceutical company’s stock valued at $270,000 after buying an additional 33 shares during the last quarter. Sullivan Bruyette Speros & Blaney LLC increased its position in Gilead Sciences by 0.6% in the fourth quarter. Sullivan Bruyette Speros & Blaney LLC now owns 6,779 shares of the biopharmaceutical company’s stock valued at $485,000 after buying an additional 42 shares during the last quarter. Finally, Albion Financial Group UT increased its position in Gilead Sciences by 0.6% in the third quarter. Albion Financial Group UT now owns 6,771 shares of the biopharmaceutical company’s stock valued at $536,000 after buying an additional 43 shares during the last quarter. Hedge funds and other institutional investors own 74.62% of the company’s stock.

The firm has a market capitalization of $88.05 billion, a PE ratio of 6.18 and a beta of 1.11. The firm has a 50-day moving average of $72.72 and a 200-day moving average of $75.94.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 7th. The biopharmaceutical company reported $2.70 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.61 by $0.09. Gilead Sciences had a net margin of 47.74% and a return on equity of 100.57%. The firm had revenue of $7.30 billion for the quarter, compared to analysts’ expectations of $7.16 billion. During the same quarter in the prior year, the business earned $3.32 EPS. The business’s quarterly revenue was down 13.9% on a year-over-year basis. Analysts expect that Gilead Sciences, Inc. will post $10.68 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 30th. Shareholders of record on Thursday, March 16th will be paid a dividend of $0.52 per share. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.47. The ex-dividend date is Tuesday, March 14th. This represents a $2.08 dividend on an annualized basis and a yield of 3.11%. Gilead Sciences’s dividend payout ratio (DPR) is presently 17.44%.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

Related posts

Leave a Comment

Gilead Sciences, Inc. (GILD) Hits New 52-Week Low After Analyst Downgrade

Gilead Sciences, Inc. (GILD) Hits New 52-Week Low After Analyst Downgrade

Gilead Sciences, Inc. (NASDAQ:GILD) shares hit a new 52-week low during trading on Wednesday after RBC Capital Markets lowered their price target on the stock to $75.00. The company traded as low as $65.83 and last traded at $65.81, with a volume of 3,304,798 shares. The stock had previously closed at $73.13.

GILD has been the subject of a number of other research reports. William Blair reiterated an “outperform” rating on shares of Gilead Sciences in a research note on Saturday, January 28th. Cowen and Company set a $100.00 target price on shares of Gilead Sciences and gave the company a “buy” rating in a research note on Wednesday, January 18th. Evercore ISI set a $90.00 target price on shares of Gilead Sciences and gave the company a “buy” rating in a research note on Saturday, October 15th. Goldman Sachs Group, Inc. (The) reiterated a “hold” rating and issued a $81.00 target price on shares of Gilead Sciences in a research note on Friday, January 13th. Finally, Robert W. Baird reiterated an “outperform” rating and issued a $100.00 target price (down previously from $122.00) on shares of Gilead Sciences in a research note on Tuesday, October 18th. One equities research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, fourteen have given a buy rating and two have issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $90.68.

In other Gilead Sciences news, insider John C. Martin sold 73,337 shares of Gilead Sciences stock in a transaction dated Tuesday, January 3rd. The shares were sold at an average price of $73.59, for a total value of $5,396,869.83. Following the sale, the insider now owns 3,204,433 shares of the company’s stock, valued at $235,814,224.47. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director John W. Madigan sold 105,000 shares of Gilead Sciences stock in a transaction dated Friday, November 18th. The stock was sold at an average price of $74.86, for a total transaction of $7,860,300.00. Following the completion of the sale, the director now directly owns 121,761 shares in the company, valued at approximately $9,115,028.46. The disclosure for this sale can be found here. Corporate insiders own 1.40% of the company’s stock.

Institutional investors have recently bought and sold shares of the company. Tarbox Group Inc. increased its position in Gilead Sciences by 0.4% in the third quarter. Tarbox Group Inc. now owns 6,522 shares of the biopharmaceutical company’s stock valued at $516,000 after buying an additional 27 shares during the last quarter. West Oak Capital LLC increased its position in Gilead Sciences by 0.7% in the third quarter. West Oak Capital LLC now owns 4,449 shares of the biopharmaceutical company’s stock valued at $352,000 after buying an additional 32 shares during the last quarter. Alpha Windward LLC increased its position in Gilead Sciences by 1.0% in the third quarter. Alpha Windward LLC now owns 3,410 shares of the biopharmaceutical company’s stock valued at $270,000 after buying an additional 33 shares during the last quarter. Sullivan Bruyette Speros & Blaney LLC increased its position in Gilead Sciences by 0.6% in the fourth quarter. Sullivan Bruyette Speros & Blaney LLC now owns 6,779 shares of the biopharmaceutical company’s stock valued at $485,000 after buying an additional 42 shares during the last quarter. Finally, Albion Financial Group UT increased its position in Gilead Sciences by 0.6% in the third quarter. Albion Financial Group UT now owns 6,771 shares of the biopharmaceutical company’s stock valued at $536,000 after buying an additional 43 shares during the last quarter. Hedge funds and other institutional investors own 74.62% of the company’s stock.

The firm has a market capitalization of $88.05 billion, a PE ratio of 6.18 and a beta of 1.11. The firm has a 50-day moving average of $72.72 and a 200-day moving average of $75.94.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 7th. The biopharmaceutical company reported $2.70 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.61 by $0.09. Gilead Sciences had a net margin of 47.74% and a return on equity of 100.57%. The firm had revenue of $7.30 billion for the quarter, compared to analysts’ expectations of $7.16 billion. During the same quarter in the prior year, the business earned $3.32 EPS. The business’s quarterly revenue was down 13.9% on a year-over-year basis. Analysts expect that Gilead Sciences, Inc. will post $10.68 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 30th. Shareholders of record on Thursday, March 16th will be paid a dividend of $0.52 per share. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.47. The ex-dividend date is Tuesday, March 14th. This represents a $2.08 dividend on an annualized basis and a yield of 3.11%. Gilead Sciences’s dividend payout ratio (DPR) is presently 17.44%.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

Related posts

Leave a Comment